{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T16:03:41Z","timestamp":1780157021393,"version":"3.54.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":126,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This analysis of the multinational ADVANCE study evaluated how the healthcare professional\u2019s (HCP\u2019s) role and setting of care influence attitudes, perceptions, and utilization of long-acting injectable antipsychotics (LAIs) for schizophrenia treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>A cross-sectional survey was conducted among HCPs from 8 countries, capturing data on practice characteristics, LAI prescribing behaviors, confidence, and challenges related to LAIs, and treatment objectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>A total of 791 HCPs were categorized by role (psychiatrist [n\u2009=\u2009490] or psychiatric nonphysician [n\u2009=\u2009301]) and by setting of care (inpatient [IP] psychiatric ward [n\u2009=\u2009260], hospital-based outpatient [OP] clinic [n\u2009=\u2009174], community\/psychiatric OP clinic [n\u2009=\u2009227], and independent practice [n\u2009=\u2009107]). Psychiatrists were more likely to identify as early users of LAIs and demonstrated higher confidence with LAI use than psychiatric nonphysicians, who, despite lower confidence and lower likelihood of prescribing LAIs, reported higher patient acceptance rates at first recommendation. Among care settings, IP psychiatric ward HCPs had the highest likelihood of prescribing LAIs but the lowest confidence levels, whereas independent practice HCPs exhibited high confidence yet the lowest likelihood of prescribing LAIs. Independent practice HCPs reported having the least support staff and cited lack of time as a challenge to LAI use, suggesting that systemic barriers and HCP burden may influence LAI utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Together, these findings underscore the importance of tailored educational resources addressing both the HCP\u2019s role and practice environment to enhance confidence, facilitate effective patient discussions, and ultimately improve LAI utilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schizbullopen\/sgag019","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:11:50Z","timestamp":1777637510000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Healthcare Professional Role and Care Setting on Attitudes Toward Long-Acting Injectable Antipsychotics for Schizophrenia: A Subgroup Analysis of the Multinational ADVANCE Study"],"prefix":"10.1093","volume":"7","author":[{"given":"Kelli R","family":"Franzenburg","sequence":"first","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D LLC, Global Medical Affairs , West Chester, PA 19380, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hansen","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D LLC, North America Medical Affairs , Parsippany, NJ 07054, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[{"name":"Teva UK Limited, Global Medical Affairs , Harlow CM20 2FB, \u00a0","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Yaari","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd., Global Medical Affairs , Tel Aviv 6944020, \u00a0","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-8480","authenticated-orcid":false,"given":"Sigal","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd., Global Health Economics and Outcome Research , Netanya 4231301, \u00a0","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kameron","family":"Sedigh","sequence":"additional","affiliation":[{"name":"Syneos Health New York, Commercial Advisory Group , New York, NY 10281, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Yu","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D LLC, Global Medical Affairs , West Chester, PA 19380, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[{"name":"kbo-Klinik f\u00fcr Psychiatrie und Psychotherapie Nord, Psychiatry 80804, M\u00fcnchen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sajatovic","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026053011365362700_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \"just the facts\" 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr Res"},{"key":"2026053011365362700_ref2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br Med Bull"},{"key":"2026053011365362700_ref3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"key":"2026053011365362700_ref4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"2026053011365362700_ref5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29\u2009823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2026053011365362700_ref6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14656566.2023.2181073","article-title":"Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges","volume":"24","author":"Haddad","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"2026053011365362700_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"2026053011365362700_ref8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/NDT.S369494","article-title":"Understanding the health system conditions affecting the use of long-acting injectable antipsychotics in the treatment of schizophrenia in clinical practice: a US healthcare provider survey","volume":"18","author":"Zhdanava","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026053011365362700_ref9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12888-025-06565-1","article-title":"Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey","volume":"25","author":"Velligan","year":"2025","journal-title":"BMC Psychiatry."},{"key":"2026053011365362700_ref10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.9740\/mhc.2022.08.232","article-title":"Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners","volume":"12","author":"Schwartz","year":"2022","journal-title":"Ment Health Clin"},{"key":"2026053011365362700_ref11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12888-022-03846-x","article-title":"Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey","volume":"22","author":"Keenan","year":"2022","journal-title":"BMC Psychiatry"},{"key":"2026053011365362700_ref12","doi-asserted-by":"publisher","first-page":"1645328","DOI":"10.3389\/fpsyt.2025.1645328","article-title":"Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study","volume":"16","author":"Franzenburg","year":"2025","journal-title":"Front Psychiatry"},{"key":"2026053011365362700_ref13","doi-asserted-by":"publisher","first-page":"sgaf032","DOI":"10.1093\/schizbullopen\/sgaf032","article-title":"Attitudes driving regional differences in long-acting injectable antipsychotic utilization for schizophrenia among healthcare professionals, patients, and caregivers (ADVANCE): results from a multinational survey study","volume":"7","author":"Franzenburg","year":"2025","journal-title":"Schizophr Bull Open"},{"key":"2026053011365362700_ref14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1471-244X-13-261","article-title":"Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia","volume":"13","author":"Potkin","year":"2013","journal-title":"BMC Psychiatry."},{"key":"2026053011365362700_ref15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12888-020-02530-2","article-title":"Attitudes of European physicians towards the use of long-acting injectable antipsychotics","volume":"20","author":"Patel","year":"2020","journal-title":"BMC Psychiatry"},{"key":"2026053011365362700_ref16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2026053011365362700_ref17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890424841","volume-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia","author":"American Psychiatric Association","year":"2020","edition":"3rd ed"},{"key":"2026053011365362700_ref18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"2026053011365362700_ref19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4088\/PCC.08r00612","article-title":"Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review","volume":"11","author":"Masand","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2026053011365362700_ref20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12888-023-04928-0","article-title":"Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery","volume":"23","author":"Arango","year":"2023","journal-title":"BMC Psychiatry."}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgag019\/68244857\/sgag019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag019\/68244857\/sgag019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag019\/68244857\/sgag019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:36:56Z","timestamp":1780155416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgag019\/8672026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgag019","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"sgag019"}}